TERACHEM 2026 Abstract Submission

The TERACHEM 2026 abstract submission begins january 15, 2026 and closes march 31, 2026

In keeping with tradition, nearly the entire program will be built on the strength of colleagues’ submission of their research. Abstracts will be blindly scored by a large list of qualified reviewers.

Organizers strongly encourage colleagues to refer to the Consensus nomenclature rules for radiopharmaceutical chemistry – setting the record straight. This important guide was developed by an international working group in order to promote the clear and appropriate use of terms and to provide consensus on the utilization of a standardized nomenclature pertinent to the field.

List of Abstract Categories:

  • Radionuclide Production & Targetry

  • Technetium and Rhenium Chemistry

  • Other Radiometals & Ligand Design

  • Preclinical Development of Metal Based Radiopharmaceuticals & Radiopharmacology

  • Radiotherapy and Radiotheragnostics

Abstract submission guidelines

(Also found in the submission system)

  1. The body of the abstract is limited to 500 words; this includes any words used in tables as part of the abstract body.

  2. Abstract title and author/affiliation information do not count against the 500 word total.

  3. Only one .JPG image may be uploaded, though you may combine up to three images into one .JPG file. Images will be displayed electronically in color.

  4. Organize your abstract according to the standard subtitles: Objectives, Methods, Results, Conclusions, and Acknowledgments/References. If you want to view an abstract example, download Guidelines and Example Abstracts for Authors.

  5. You are also strongly encouraged to follow the nomenclature guidelines (DOI: 10.1016/j.nucmedbio.2017.09.004) recently published by an international working group.

  6. Use only one table in the body of your abstract or, possibly, two small tables.

  7. Your abstracts must include actual data and not simply be an overview.

  8. If the abstract refers to a compound, the compound should be properly identified (not simply a number).

  9. The structure of novel compounds should be discussed in the acceptable abstract.

  10. When adding co-authors who are already in the database system, you cannot modify their affiliation or any of their profile data - the co-author must modify their own data. They can do this by visiting the profile home.